169 related articles for article (PubMed ID: 38219651)
1. Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: A cohort study from the UK Biobank.
Welsh P; Al Zabiby A; Byrne H; Benbow HR; Itani T; Farries G; Costa-Scharplatz M; Ferber P; Martin L; Brown R; Fonseca AF; Sattar N
Atherosclerosis; 2024 Feb; 389():117437. PubMed ID: 38219651
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations.
Small AM; Pournamdari A; Melloni GEM; Scirica BM; Bhatt DL; Raz I; Braunwald E; Giugliano RP; Sabatine MS; Peloso GM; Marston NA; Natarajan P
JAMA Cardiol; 2024 Apr; 9(4):385-391. PubMed ID: 38353970
[TBL] [Abstract][Full Text] [Related]
3. Burden of lipoprotein(a) for patients with atherosclerotic cardiovascular disease: A retrospective analysis from the United States.
Fonseca AF; Byrne H; Laguna A; Itani T; Studer R; Heo J; Dillon A; Ferber P; Costa-Scharplatz M
J Manag Care Spec Pharm; 2023 May; 29(5):519-529. PubMed ID: 37121256
[No Abstract] [Full Text] [Related]
4. Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease.
Berman AN; Biery DW; Besser SA; Singh A; Shiyovich A; Weber BN; Huck DM; Divakaran S; Hainer J; Kaur G; Blaha MJ; Cannon CP; Plutzky J; Januzzi JL; Booth JN; López JAG; Kent ST; Nasir K; Di Carli MF; Bhatt DL; Blankstein R
J Am Coll Cardiol; 2024 Mar; 83(9):873-886. PubMed ID: 38418000
[TBL] [Abstract][Full Text] [Related]
5. Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank.
Patel AP; Wang (汪敏先) M; Pirruccello JP; Ellinor PT; Ng K; Kathiresan S; Khera AV
Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):465-474. PubMed ID: 33115266
[TBL] [Abstract][Full Text] [Related]
6. Elevated Lp(a) (Lipoprotein[a]) Levels Increase Risk of 30-Day Major Adverse Cardiovascular Events in Patients Following Carotid Endarterectomy.
Waissi F; Dekker M; Timmerman N; Hoogeveen RM; van Bennekom J; Dzobo KE; Schnitzler JG; Pasterkamp G; Grobbee DE; de Borst GJ; Stroes ESG; de Kleijn DPV; Kroon J
Stroke; 2020 Oct; 51(10):2972-2982. PubMed ID: 32878565
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort.
Wong ND; Fan W; Hu X; Ballantyne C; Hoodgeveen RC; Tsai MY; Browne A; Budoff MJ
J Am Coll Cardiol; 2024 Apr; 83(16):1511-1525. PubMed ID: 38631771
[TBL] [Abstract][Full Text] [Related]
8. Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the Clinical Practice Research Datalink.
Morgan CL; Durand A; McCormack T; Hughes E; Berni TR; Lahoz R
BMJ Open; 2023 Nov; 13(11):e064541. PubMed ID: 38030254
[TBL] [Abstract][Full Text] [Related]
9. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients.
Longenecker JC; Klag MJ; Marcovina SM; Liu YM; Jaar BG; Powe NR; Fink NE; Levey AS; Coresh J
J Am Soc Nephrol; 2005 Jun; 16(6):1794-802. PubMed ID: 15800123
[TBL] [Abstract][Full Text] [Related]
10. Development and Multinational Validation of a Novel Algorithmic Strategy for High Lp(a) Screening.
Aminorroaya A; Dhingra LS; Oikonomou EK; Saadatagah S; Thangaraj P; Shankar SV; Spatz ES; Khera R
medRxiv; 2023 Sep; ():. PubMed ID: 37790355
[TBL] [Abstract][Full Text] [Related]
11. Independent Relationship of Lipoprotein(a) and Carotid Atherosclerosis With Long-Term Risk of Cardiovascular Disease.
Qi Y; Duan Y; Deng Q; Yang N; Sun J; Li J; Hu P; Liu J; Liu J
J Am Heart Assoc; 2024 May; 13(9):e033488. PubMed ID: 38639362
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data.
Lindh M; Banefelt J; Fox KM; Hallberg S; Tai MH; Eriksson M; Villa G; Svensson MK; Qian Y
Eur Heart J Qual Care Clin Outcomes; 2019 Jul; 5(3):225-232. PubMed ID: 30649251
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: A real-world evidence study.
Chen G; Farris MS; Cowling T; Pinto L; Rogoza RM; MacKinnon E; Champsi S; Anderson TJ
Clin Cardiol; 2021 Nov; 44(11):1613-1620. PubMed ID: 34585767
[TBL] [Abstract][Full Text] [Related]
14. Burden of elevated lipoprotein(a) among patients with atherosclerotic cardiovascular disease: Evidence from a systematic literature review and feasibility assessment of meta-analysis.
Orfanos P; Fonseca AF; Hu X; Gautam R; Montgomery G; Studer R; Kaur J; Saxena N; Kaushik N
PLoS One; 2023; 18(11):e0294250. PubMed ID: 37983217
[TBL] [Abstract][Full Text] [Related]
15. Determinants of Incident Atherosclerotic Cardiovascular Disease Events and All-Cause Mortality in Patients With Age-Related Macular Degeneration: Prospective Cohort Study of UK Biobank.
Wang Y; Liang Y; Seth I; Wu G; Du Z; Huang Y; Shang X; Liu S; Hu Y; Fang Y; Zhu Z; Hu Y; Zhang X; Yang X; Yu H
Asia Pac J Ophthalmol (Phila); 2023 May-Jun 01; 12(3):293-302. PubMed ID: 37249901
[TBL] [Abstract][Full Text] [Related]
16. Elevated lipoprotein(a) levels are associated with coronary artery calcium scores in asymptomatic individuals with a family history of premature atherosclerotic cardiovascular disease.
Verweij SL; de Ronde MWJ; Verbeek R; Boekholdt SM; Planken RN; Stroes ESG; Pinto-Sietsma SJ
J Clin Lipidol; 2018; 12(3):597-603.e1. PubMed ID: 29550494
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein(a) and prevalent cardiovascular disease in a dialysis population: The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study.
Longenecker JC; Coresh J; Marcovina SM; Powe NR; Levey AS; Giaculli F; Fink NE; Klag MJ
Am J Kidney Dis; 2003 Jul; 42(1):108-16. PubMed ID: 12830462
[TBL] [Abstract][Full Text] [Related]
18. Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease.
Hedegaard BS; Bork CS; Kaltoft M; Klausen IC; Schmidt EB; Kamstrup PR; Langsted A; Nordestgaard BG
J Am Coll Cardiol; 2022 Nov; 80(21):1998-2010. PubMed ID: 36396201
[TBL] [Abstract][Full Text] [Related]
19. When Does a Calcium Score Equate to Secondary Prevention?: Insights From the Multinational CONFIRM Registry.
Budoff MJ; Kinninger A; Gransar H; Achenbach S; Al-Mallah M; Bax JJ; Berman DS; Cademartiri F; Callister TQ; Chang HJ; Chow BJW; Cury RC; Feuchtner G; Hadamitzky M; Hausleiter J; Kaufmann PA; Leipsic J; Lin FY; Kim YJ; Marques H; Pontone G; Rubinshtein R; Shaw LJ; Villines TC; Min JK;
JACC Cardiovasc Imaging; 2023 Sep; 16(9):1181-1189. PubMed ID: 37227328
[TBL] [Abstract][Full Text] [Related]
20. Elevated Lipoprotein(a) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study.
Mohammadi-Shemirani P; Chong M; Narula S; Perrot N; Conen D; Roberts JD; Thériault S; Bossé Y; Lanktree MB; Pigeyre M; Paré G
J Am Coll Cardiol; 2022 Apr; 79(16):1579-1590. PubMed ID: 35450575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
